13,878 Abbott Laboratories $ABT Shares Sold by Stokes Capital Advisors LLC

Stokes Capital Advisors LLC lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 30.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 31,056 shares of the healthcare product maker’s stock after selling 13,878 shares during the quarter. Stokes Capital Advisors LLC’s holdings in Abbott Laboratories were worth $3,069,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of ABT. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories in the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter valued at about $26,000. Abound Financial LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Prudent Man Investment Management Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $33,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Up 1.2%

Shares of Abbott Laboratories stock opened at $99.71 on Friday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $134.50. The firm has a market cap of $172.53 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 1.83 and a beta of 0.59. The company has a 50-day moving average of $106.25 and a 200 day moving average of $98.35. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. Abbott Laboratories’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Wall Street Analysts Forecast Growth

ABT has been the subject of several recent research reports. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Piper Sandler restated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Royal Bank Of Canada reiterated an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Bank of America dropped their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Finally, Barclays began coverage on shares of Abbott Laboratories in a research report on Wednesday. They issued an “overweight” rating and a $120.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.88.

Abbott Laboratories Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.